US2014179611A1PendingUtilityA1

Tribonectins

61
Individually held — no corporate assignee on recordPriority: Apr 23, 1999Filed: Jan 29, 2014Published: Jun 26, 2014
Est. expiryApr 23, 2019(expired)· nominal 20-yr term from priority
Inventors:Gregory D. Jay
A61P 41/00A61P 9/00A61P 43/00A61P 19/10A61K 38/1709A61K 48/00C07K 14/47A61P 17/02A61P 19/02A61K 38/00C07K 14/475
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention features a tribonectin and a method of tribosupplementation carried out by administering tribonectins directly to an injured or arthritic joint.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A tribonectin comprising a polypeptide the amino acid sequence of which comprises at least one but less than  76  subunits, wherein
 (a) each subunit comprises at least 7 amino acids; and 
 (b) the amino acid sequence of said subunit is at least 50% identical to SEQ ID NO:3, wherein a non-identical amino acid is a conservative amino acid substitution. 
 
     
     
         2 . The tribonectin of  claim 1 , wherein the amino acid sequence of said subunit is SEQ ID NO:3. 
     
     
         3 . The tribonectin of  claim 1 , wherein said tribonectiri further comprises one or more repeats of the amino acid sequence of SEQ ID NO:4. 
     
     
         4 . The tribonectin of  claim 1 , wherein said tribonectin is characterized as reducing the coefficient of friction between bearing surfaces. 
     
     
         5 . The tribonectin of  claim 1 , wherein said tribonectin is characterized as reducing the coefficient of friction between bearing surfaces in vitro. 
     
     
         6 . The tribonectin of  claim 1 , wherein said tribonectin is characterized as reducing the coefficient of friction between bearing surfaces in vivo. 
     
     
         7 . The tribonectin of  claim 1 , wherein said tribonectin does not substantially increase the viscosity of a solution to which it is added. 
     
     
         8 . The tribonectin of  claim 1 , wherein said tribonectin comprises an O-linked oligosaccharide. 
     
     
         9 . The tribonectin of  claim 1 , wherein said oligosaccharide is an N-acetylgalactosamine-galactose. 
     
     
         10 . The tribonectin of  claim 1 , wherein at least 10% of said tribonectin is glycosylated. 
     
     
         11 . The tribonectin of  claim 1 , wherein at least 40% of said tribonectin is glycosylated. 
     
     
         12 . The tribonectin of  claim 1 , wherein the molecular weight of said tribonectin is in the range of 200-280 kDa. 
     
     
         13 . The tribonectin of  claim 1 , wherein said polypeptide comprises a fragment of megakaryocyte stimulating factor. 
     
     
         14 . The triboriectin of  claim 1 , wherein said polypeptide comprises an amino acid sequence that is at least 50% identical to the sequence of residues 200-1140, inclusive, of SEQ ID NO:1. 
     
     
         15 . The tribonectin of  claim 14 , wherein said polypeptide comprises the amino acid sequence of residues 200-1140, inclusive, of SEQ ID N 0 :1. 
     
     
         16 . The tribonectin of  claim 1 , wherein said polypeptide comprises an amino acid sequence that is at least 50% identical to the sequence of residues 200-1167, inclusive, of SEQ ID NO:1. 
     
     
         17 . The tribonectin of  claim 16 , wherein said polypeptide comprises the amino acid sequence of residues 200-1167, inclusive, of SEQ ID NO:1. 
     
     
         18 . The tribonectin of  claim 1 , wherein said polypeptide comprises an amino acid sequence that is at least 50% identical to the sequence of residues 200-1212, inclusive, of SEQ ID NQ:1. 
     
     
         19 . The tribonectin of  claim 18 , wherein said polypeptide comprises the amino acid sequence of residues 200-1212, inclusive, of SEQ ID NO:1. 
     
     
         20 . The tribonectjn of  claim 1 , wherein said polypeptide comprises an amino acid sequence that is at least 50% identical to the sequence of residues 200-1263, inclusive, of SEQ ID NO:1. 
     
     
         21 . The tribonectin of  claim 20 , wherein said polypeptide comprises the amino acid sequence of residues 200-1263, inclusive, of SEQ ID NO:1. 
     
     
         22 . The tribonectin of  claim 1 , wherein said polypeptide lacks the amino acid sequence of residues 1-24, inclusive, of SEQ ID NO:1. 
     
     
         23 . The tribonectin of  claim 1 , wherein said polypeptide lacks the amino acid sequence of residues 67-104, inclusive of SEQ ID NO:1. 
     
     
         24 . An isolated nucleic acid molecule encoding a tribonectin. 
     
     
         25 . The nucleic acid of  claim 24 , wherein said nucleic acid comprises the sequence of nucleotides 631-3453, inclusive, of SEQ ID NO:2. 
     
     
         26 . A method of lubricating a mammalian joint, comprising contacting said joint with the tribonectin of  claim 1 . 
     
     
         27 . The method of  claim 26 , wherein said joint is an articulating joint of a human. 
     
     
         28 . The method of  claim 26 , wherein said joint is an articulating joint of a dog. 
     
     
         29 . The method of  claim 26 , wherein said joint is an articulating joint of a horse. 
     
     
         30 . The method of  claim 26 , wherein said tribonectin is administered intra-articularly. 
     
     
         31 . A method of lubricating a mammalian joint, comprising contacting said joint with the nucleic acid of  claim 24 . 
     
     
         32 . A biocompatible composition comprising a tribonectin, wherein said composition is in a form suitable for the inhibition of tissue adhesion formation. 
     
     
         33 . The composition of  claim 32 , wherein said tribonectin is in the form of a membrane, foam, gel, or fiber. 
     
     
         34 . A method inhibiting adhesion formation between a first surface and a second surface in a mammal, said method comprising placing a tribonectin between said first and second surfaces in an amount sufficient to prevent adhesion of said surfaces in said mammal. 
     
     
         35 . The method of  claim 34 , wherein said first surface and said second surface are both injured tissues of said mammal. 
     
     
         36 . The method of  claim 34 , wherein said first or said second surface is an artificial device. 
     
     
         37 . The method of  claim 36 , wherein said artificial device is an orthopedic implant. 
     
     
         38 . The method of  claim 34 , wherein said tribonectin is in the form of a membrane, foam, gel, or fiber. 
     
     
         39 . The method of  claim 34 , wherein said injury is due to a surgical incision. 
     
     
         40 . The method of  claim 34 , wherein said injury is due to trauma. 
     
     
         41 . A method for diagnosing an osteoarthritis or a predisposition thereto in a mammal, comprising measuring the amount of a fragment of megakaryocyte stimulating factor in a biological sample derived from said mammal, wherein an increase in said amount compared to a control indicates that said mammal suffers from osteoarthritis or is predisposed to developing osteoarthritis. 
     
     
         42 . The method of  claim 41 , wherein said biological sample is synovial fluid, blood, serum, or urine. 
     
     
         43 . The method of  claim 41 , wherein said MSF fragment comprises the amino acid sequence of SEQ ID NO:3. 
     
     
         44 . The method of  claim 41 , wherein said MSF fragment comprises the amino acid sequence of SEQ ID NO:5. 
     
     
         45 . The method of  claim 41 , wherein said MSF fragment comprises the amino acid sequence of SEQ ID NO:6.

Join the waitlist — get patent alerts

Track US2014179611A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.